By Infinium Global Research Aug, 2020
The Global
Antithrombin Market is expected to grow at a CAGR of 5.15% between 2020
and 2026 in terms of value. The increasing incidences of hereditary and
acquired antithrombin deficiency are majorly influencing the growth of the antithrombin market. Hereditary antithrombin deficiency is a thrombogenic
disorder associated with a 50–90% lifetime risk of venous thromboembolism.
Antithrombin has been increasingly used for the treatment and diagnosis of
hereditary and acquired hereditary antithrombin deficiency, which increases its
demand as the prevalence increases along with the rising population. Moreover,
the growing usage of antithrombin-based anticoagulants is anticipated to drive
the demand for antithrombin in the pharmaceutical sector. The thrombotic complications
of atherosclerosis, such as acute coronary syndrome and ischemic stroke are
believed to be fatal. The clopidogrel has played an important role in boosting
the antithrombotic market over the past few years. Over the past two decades, pharmaceutical companies have taken efforts to develop antithrombotics that
function by inhibiting key enzymes positioned at higher levels of the
coagulation system, further propelling the market.
However, the high cost of antithrombin based therapies is
expected to hamper the growth of the market. Antithrombin is a more expensive
treatment to use compared with the other therapies as FFP, which is leading to a shift of preference towards substitute therapies. Nevertheless, the development of
novel recombinant Antithrombin is anticipated to provide new opportunities for
the antithrombin manufacturers. Plasma-derived antithrombin (AT) concentrates
have been used for the management of hereditary and acquired deficiencies since
the early 1980s. Recombinant versions of other blood factors and their
derivatives are increasingly becoming available, providing a safe and abundant
supply of these important therapeutics. Moreover, engineered antithrombin will
also gain clinical significance as it helps to prevent various perioperative
and peripartum thromboembolic blood clots. Hence, the development of such novel
recombinant Antithrombin is expected to create new opportunities for the
antithrombin manufacturers over the forecast period.